Promethazine IM Administration: No Dilution Required
Promethazine injection should NOT be diluted when given intramuscularly—administer undiluted via deep IM injection. 1
Administration Guidelines for IM Route
Deep intramuscular injection is the preferred and safest parenteral route for promethazine administration. 1, 2 The FDA drug labeling explicitly states that promethazine should be given by deep IM injection without any mention of dilution requirements for this route. 1
Key Administration Points:
- No dilution needed: Administer the medication undiluted directly into deep muscle tissue 1
- Preferred route: IM administration is specifically recommended over IV due to significantly lower risk of severe tissue injury 1, 2
- Standard dosing: Adult doses typically range from 12.5-50 mg depending on indication 1
Critical Safety Considerations
The emphasis on deep IM injection stems from promethazine's severe vesicant properties and high caustic potential to blood vessels and surrounding tissues. 3, 2
Why IM is Preferred Over IV:
- Eliminates risk of intra-arterial injection, which can cause severe arteriospasm and gangrene requiring amputation 1
- Prevents perivascular extravasation that leads to tissue necrosis, thrombophlebitis, and potentially fasciotomy or amputation 1, 3
- Avoids intraneuronal/perineuronal infiltration causing palsies and paralysis 1
Common Pitfall to Avoid:
Do not confuse IM and IV administration requirements. When promethazine must be given IV (which should be avoided when possible), it requires dilution to ≤25 mg/mL and slow administration at ≤25 mg/minute through functioning IV tubing. 1 However, for IM administration—the recommended route—no dilution is necessary or specified. 1
Special Populations
- Pediatric patients <2 years: Promethazine is contraindicated due to fatal respiratory depression risk 1
- Pediatric patients ≥2 years: Use lowest effective dose (typically half adult dose); deep IM remains preferred route 1
- Compromised respiratory function: Avoid promethazine entirely due to respiratory depression risk 1
The 2023 FDA labeling update reinforced the preference for IM administration and added a black box warning about tissue injury risks with improper administration. 2